This document is a publication of a patent application, not a final rule or enforcement action. The application, filed by ADAGENE PTE. LTD., describes methods and compositions for treating cancers using anti-CTLA4 antibodies, particularly for cancers resistant to PD-1 or PD-L1 inhibitors. It includes details on combination therapies.

As this is a patent application, there are no immediate compliance obligations or deadlines for regulated entities. However, companies involved in oncology drug development, particularly those working with immunotherapy or CTLA4 inhibitors, should note this filing as it may indicate future patent protection and competitive landscape shifts in the field.